15-PGDH阻害剤の知識と構造に基づく薬剤設計
Leela S Dodda1, Sebastien Campos2, David Ciccone1
1Nimbus Therapeutics, Boston, Massachusetts 02210, United States.
Journal of medicinal chemistry
|August 27, 2025
まとめ
15- プロスタグランジン脱水酵素 (15- PGH) の抑制は,組織再生のためのプロスタグランジンE2 (PGE2) レベルを高めることができます. この研究では,構造ベースの設計と計算方法を使用して新しい15-PGDH阻害剤を開発し,その治療的可能性を検証しました.
科学分野:
- 生物化学
- 薬理学について
- コンピュータ化学
背景:
- プロスタグランジンE2 (PGE2) は免疫細胞機能と組織再生に不可欠です.
- 15 - プロスタグラジン脱水素酵素 (15- PGDH) はPGE2を不活性化させ,その抑制を治療目標とする.
研究 の 目的:
- 小分子阻害剤で15-PGDHの最初のコクリスタル構造を解決する.
- 構造ベースのアプローチと計算ツールを使用して,新しい15-PGDH阻害剤を合理的に設計する.
- PGE2レベルを15-PGDH抑制によって上昇させるという治療的仮説を検証する.
主な方法:
- 小分子阻害剤による15-PGDHの共結晶化
- 構造に基づいた薬物設計です
- FEP+とWaterMapを含む高度な計算方法
- 合成の優先順位を導くための機械学習 (ML) モデル開発
- 腸内PGE2レベルを測定するためにマウスの体内投与 (IP)
主要な成果:
- 阻害剤に結合する15-PGDHの最初のコクリスタル構造が決定された.
- 合理的な設計と計算モデリングを通じて,新しい15-PGDH阻害剤のシリーズが開発されました.
- 機械学習モデルによって 合成化合物の優先順位が決定されました
- コロンのPGE2濃度上昇に成功した.
結論:
- 構造ベースの設計と計算方法は,強力な15-PGDH阻害剤の開発に有効です.
- PGE2レベルを上昇させるには有効な戦略です.
- 開発された化合物は,強化されたPGE2シグナリングから恩恵を受ける状態に対する治療的可能性を秘めています.
さらに関連する動画
13:35Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
Published on: May 23, 2025
586
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.5K
関連する概念動画
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Prodrugs
2.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.8K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K
